Q1 2026 · 13F-HR
Remedium Capital Partners, LLCholdings as filed
Filed 2026-05-13 · accession 0002104501-26-000008
$319.8M
Reported value
6
Positions
2026-03-31
Period end
The Brief · Remedium Capital Partners, LLC · Q1 2026
AI · grounded in 13F
Remedium Capital Partners, LLC increased its position in Damora Therapeutics Inc DMRA by 1597.87%. The fund also accumulated shares in Spyre Therapeutics Inc SYRE and Oruka Therapeutics Inc ORKA by 30.98% and 21.69%, respectively. These additions brought the fund's total position count to 6 with total AUM of $319.77M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00773J202 | SYRE | Spyre Therapeutics Inc | $96.2M | 30.1% | 1,907,327 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics Inc | $92.7M | 29.0% | 1,889,115 | Common | SOLE |
| 36322Q206 | DMRA | Damora Therapeutics Inc | $53.0M | 16.6% | 2,045,473 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $49.1M | 15.4% | 583,591 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences Inc | $22.2M | 6.93% | 1,577,750 | Common | SOLE |
| 38000Q201 | — | Crescent Biopharma Inc | $6.6M | 2.08% | 361,250 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.